GGrantIndex
← Search

BROAD SPECTRUM MONOCLONAL ANTIBODY-BASED THERAPEUTIC FOR BOTULISM

$3,045,884N01FY2015AINIH

Investigators

Abstract

This contract supports the advanced development of promising biodefense therapeutic candidates/products with broad spectrum activity. The research and development activities supported will allow candidate therapeutic countermeasures to progress through the product development pipeline, and includes preclinical/non-clinical and clinical IND development activities.

View original record on NIH RePORTER →